Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease

Journal of Virological Methods

Volumn 169, Issue 1, 2010, Pages 79-86

  Fachiroh, Jajah ^a   Stevens, Servi J C ^b,c   Haryana, Sofia M ^a   Middeldorp, Jaap M ^b  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epstein Barr virus; Recombinant VCA p40+18; Serology

Indexed keywords

CAPSID PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; PROTEIN BDRF1; PROTEIN BFRF3; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; INFECTIOUS MONONUCLEOSIS; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; TUMOR BIOPSY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOPSY; BLOTTING, WESTERN; CAPSID PROTEINS; CHROMATOGRAPHY, AFFINITY; EPSTEIN-BARR VIRUS INFECTIONS; ESCHERICHIA COLI; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN M; INFECTIOUS MONONUCLEOSIS; MOLECULAR WEIGHT; NASOPHARYNGEAL NEOPLASMS; RECOMBINANT FUSION PROTEINS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; VIROLOGY;

ESCHERICHIA COLI; HUMAN HERPESVIRUS 4; MIRIDAE;

EID: 77956186271     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.07.001     Document Type: Article

References (46)

1. Ambinder R.F., Mann R.B. Detection and characterization of Epstein-Barr virus in clinical specimens. Am. J. Pathol. 1994, 145:239-252.
2. Bhaduri-McIntosh S., Landry M., Nikiforow S., Rotenberg M., El-Guindy A., Miller G. Serum IgA antibodies to Epstein-Barr virus(EBV) early lytic antigens are present in primary EBV infection. J. Infect. Dis. 2007, 195:483-492.
3. Buisson M., Fleurent B., Mak M., Morand P., Chan L., Ng A., Guan M., Chin D., Seigneurin J.M. Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. J. Clin. Microbiol. 1999, 37:2709-2714.
4. Chan K., Gu Y., Ng F., Ng P., Seto W., Sham J., Chua D., Wei W., Chien Y., Luk W., Zong Y.M., Ng M.H. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int. J. Cancer 2003, 105:706-709.
5. Chen J., Liu M., Hsu T., Cho S.C., Yang C. Use of bacterially-expressed antigen for detection of antibodies to the EBV-specific deoxyribonuclease in sera from patients with nasopharyngeal carcinoma. J. Virol. Methods 1993, 45:49-66.
6. Chen M., Middeldorp J., Hayward D. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J. Virol. 1993, 67:4875-4885.
7. Chow K.C., Ma J., Lin L.S., Chi K.H., Yen S.H., Liu S.M., Liu W.T., Chen W.K., Chang T.H., Chen K.Y. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. Cancer Epidemiol. Biomark. Prev. 1997, 6:363-368.
8. Connolly Y., Littler E., Sun N., Chen X., Huang P.C., Stacey S.N., Arrand J.R. Antibodies to Epstein-Barr virus thymidine kinase: a characteristic marker for the serological detection of nasopharyngeal carcinoma. Int. J. Cancer 2001, 91:692-697.
9. Dardari R., Hinderer W., Lang D., Benider A., El Gueddari B., Joab I., Benslimane A., Khyatti M. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J. Clin. Microbiol. 2001, 39:3164-3170.
10. Dardari R., Khyatti M., Benider A., Jouhadi H., Kahlain A., Cochet C., Mansouri A., El Gueddari B., Benslimane A., Joab I. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int. J. Cancer 2000, 86:71-75.
11. Dardari R., Menezes J., Drouet E., Joab I., Benider A., Bakkali H., Kanouni L., Jouhadi H., Benjaafar N., Gueddari B.E., Hassar M., Khyatti M. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. J. Clin. Virol. 2008, 41:96-103.
12. Dopatka H.D., Schuy W. Compact Epstein-Barr virus diagnosis based on a defined antigen mix and specific IgA. Res. Virol. 1996, 147:53-66.
13. Fachiroh J., Paramita D.K., Hariwiyanto B., Harijadi A., Dahlia H.L., Indrasari S.R., Kusumo H., Zeng Y.S., Schouten T., Mubarika S., Middeldorp J.M. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J. Clin. Microbiol. 2006, 44:1459-1467.
14. Fachiroh J., Prasetyanti P., Paramita D., Prasetyawati A., Anggrahini D., Haryana S., Middeldorp J. Dried-blood sampling for Epstein-Barr virus Immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. J. Clin. Microbiol. 2008, 46:1374-1380.
15. Fachiroh J., Schouten T., Hariwiyanto B., Paramita D.K., Harijadi A., Haryana S.M., Ng M.H., Middeldorp J.M. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J. Infect. Dis. 2004, 190:53-62.
16. Fan H., Nicholls J., Chua D., Chan K.H., Sham J., Lee S., Gulley M.L. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int. J. Cancer 2004, 112:1036-1041.
17. Gartner B.C., Hess R.D., Bandt D., Kruse A., Rethwilm A., Roemer K., Mueller-Lantzsch N. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin. Diagn. Lab. Immunol. 2003, 10:78-82.
18. Henle G., Henle W., Horwitz C.A. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J. Infect. Dis. 1974, 130:231-239.
19. Henle G., Henle W. Serum IgA antibodies of Epstein-Barr virus (EBV)-related antigens. A new feature of nasopharyngeal carcinoma. Bibl. Haematol. 1975, 322-325.
20. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 1976, 17:1-7.
21. Henle W., Henle G. Immunology of Epstein-Barr virus 1982, vol. 1.
22. Henle W., Henle G.E., Horwitz C.A. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum. Pathol. 1974, 5:551-565.
23. Hsu M.M., Hsu W.C., Sheen T.S., Kao C.L. Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma. Clin. Otolaryngol. Allied Sci. 2001, 26:334-338.
24. Hu B., Hong G., Li Z., Xu J., Zhu Z., Li L. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma. Biotechnol. Appl. Biochem. 2007, 47:59-69.
25. Ji M.F., Wang D.K., Yu Y.L., Guo Y.Q., Liang J.S., Cheng W.M., Zong Y.S., Chan K.H., Ng S.P., Wei W.I., Chua D.T., Sham J.S., Ng M.H. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br. J. Cancer 2007, 96:623-630.
26. Jonasson P., Liljeqvist S., Nygren P.K., Stahl S. Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli. Biotechnol. Appl. Biochem. 2002, 35:91-105.
27. Khanna R., Burrows S.R., Moss D.J. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 1995, 59:387-405.
28. Meij P., Vervoort M.B., Aarbiou J., van Dissel P., Brink A., Bloemena E., Meijer C.J., Middeldorp J.M. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J. Infect. Dis. 1999, 179:1108-1115.
29. Middeldorp J.M., Brink A.A., van den Brule A.J., Meijer C.J. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit. Rev. Oncol. Hematol. 2003, 45:1-36.
30. Middeldorp J.M., Herbrink P. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J. Virol. Methods 1988, 21:133-146.
31. Middeldorp J.M., Meloen R.H. Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. J. Virol. Methods 1988, 21:147-159.
32. Nikoskelainen J., Neel E.U., Stevens D.A. Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis. J. Clin. Microbiol. 1979, 10:75-79.
33. Okano M., Matsumoto S., Osato T., Sakiyama Y., Thiele G.M., Purtilo D.T. Severe chronic active Epstein-Barr virus infection syndrome. Clin. Microbiol. Rev. 1991, 4:129-135.
34. Papesch M., Watkins R. Epstein-Barr virus infectious mononucleosis. Clin. Otolaryngol. Allied Sci. 2001, 26:3-8.
35. Paramita D., Fachiroh J., Artama W., van Benthem E., Haryana S.M., Middeldorp J. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J. Med. Virol. 2007, 79:1710-1721.
36. Paramita D., Fachiroh J., Haryana S.M., Middeldorp J. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. J. Clin. Virol. 2008, 42:343-352.
37. Qiagen The QIAexpressionist™, a Handbook for a high-lever expression and purification of 6x-his tagged proteins 2003, Qiagen Worldwide.
38. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., Harijadi, Paramita D.K., Fachiroh J., Adham M., Tan I.B., Haryana S.M., Middeldorp J.M. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int. J. Cancer 2006, 119:608-614.
39. Stolzenberg M.C., Ooka T. Purification and properties of Epstein-Barr virus DNase expressed in Escherichia coli. J. Virol. 1990, 64:96-104.
40. Sumaya C.V. Serological testing for Epstein-Barr virus-developments in interpretation. J. Infect. Dis. 1985, 151:984-987.
41. Sumaya C.V., Ench Y. Epstein-Barr virus infectious mononucleosis in children. II. Heterophile antibody and viral-specific responses. Pediatrics 1985, 75:1011-1019.
42. Twu C.W., Wang W.Y., Liang W.M., Jan J.S., Jiang R.S., Chao J., Jin Y.T., Lin J.C. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:130-137.
43. van Grunsven W.M., Nabbe A., Middeldorp J.M. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J. Med. Virol. 1993, 40:161-169.
44. van Grunsven W.M., Spaan W.J., Middeldorp J.M. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J. Infect. Dis. 1994, 170:13-19.
45. van Grunsven W.M., van Heerde E.C., de Haard H.J., Spaan W.J., Middeldorp J.M. Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J. Virol. 1993, 67:3908-3916.
46. Wielaard F., Scherders J., Dagelinckx C., Middeldorp J.M., Sabbe L.J., Van Belzen C. Development of an antibody-capture IgM-enzyme-linked immunosorbent assay for diagnosis of acute Epstein-Barr virus infections. J. Virol. Methods 1988, 21:105-115.